Residue Glu83 plays a major role in negatively regulating α-synuclein amyloid formation

Biochemical and Biophysical Research Communications

Volumn 391, Issue 3, 2010, Pages 1415-1420

  Waxman, Elisa A ^a   Emmer, Kristel L ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Synuclein; Amyloid; Parkinson disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; DOPAMINE; EPIGALLOCATECHIN GALLATE; GLUTAMIC ACID;

ARTICLE; GENE DELETION; GENE MUTATION; HYDROPHOBICITY; INHIBITION KINETICS; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN POLYMERIZATION;

ALPHA-SYNUCLEIN; AMYLOID; CATECHIN; DOPAMINE; FLAVANONES; GLUTAMIC ACID; HUMANS; MUTATION; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 73949119538     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.12.079     Document Type: Article

References (58)

1. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., and Lansbury P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996) 13709-13715
2. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., De Silva H.A., Kittel A., and Saitoh T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14 (1995) 467-475
3. Clayton D.F., and George J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58 (1999) 120-129
4. Norris E.H., Giasson B.I., and Lee V.M. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr. Top. Dev. Biol. 60 (2004) 17-54
5. Cabin D.E., Shimazu K., Murphy D., Cole N.B., Gottschalk W., Mcllwain K.L., Orrison B., Chen A., Ellis C.E., Paylor R., Lu B., and Nussbaum R.L. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimuation in mice lacking α-synuclein. J. Neurosci. 22 (2002) 8797-8807
6. Murphy D.D., Rueter S.M., Trojanowski J.Q., and Lee V.M.Y. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20 (2000) 3214-3220
7. Chandra S., Gallardo G., Fernández-Chacón R., Schlüter O.M., and Südhof T.C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123 (2005) 359-361
8. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2 (2001) 492-501
9. Spillantini M.G., Schmidt M.L., Lee V.M.Y., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
10. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M.Y., Trojanowski J.Q., and Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 152 (1998) 879-884
11. Spillantini M.G., Crowther R.A., Jakes R., Cairns N.J., Lantos P.L., and Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett. 251 (1998) 205-208
12. Tu P.H., Galvin J.E., Baba M., Giasson B., Tomita T., Leight S., Nakajo S., Iwatsubo T., Trojanowski J.Q., and Lee V.M.Y. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol. 44 (1998) 415-422
13. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
14. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
15. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez T.E., del Ser T., Munoz D.G., and de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004) 164-173
16. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., Levecque C., Larvor L., Andrieux J., Hulihan M., Waucquier N., Defebvre L., Amouyel P., Farrer M., and Destee A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004) 1167-1169
17. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
18. Choi W., Zibaee S., Jakes R., Serpell L.C., Davletov B., Crowther R.A., and Goedert M. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett. 576 (2004) 363-368
19. Conway K.A., Harper J.D., and Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4 (1998) 1318-1320
20. Giasson B.I., Uryu K., Trojanowski J.Q., and Lee V.M.Y. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274 (1999) 7619-7622
21. Greenbaum E.A., Graves C.L., Mishizen-Eberz A.J., Lupoli M.A., Lynch D.R., Englander S.W., Axelsen P.H., and Giasson B.I. The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem. 280 (2005) 7800-7807
22. Kessler J.C., Rochet J.C., and Lansbury Jr. P.T. The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. Biochemistry 42 (2003) 672-678
23. Murray I.V., Giasson B.I., Quinn S.M., Koppaka V., Axelsen P.H., Ischiropoulos H., Trojanowski J.Q., and Lee V.M. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42 (2003) 8530-8540
24. Narhi L., Wood S.J., Steavenson S., Jiang Y., Wu G.M., Anafi D., Kaufman S.A., Martin F., Sitney K., Denis P., Louis J.C., Wypych J., Biere A.L., and Citron M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274 (1999) 9843-9846
25. Serpell L.C., Berriman J., Jakes R., Goedert M., and Crowther R.A. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. USA 97 (2000) 4897-4902
26. Giasson B.I., Murray I.V., Trojanowski J.Q., and Lee V.M.Y. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276 (2001) 2380-2386
27. Waxman E.A., Mazzulli J.R., and Giasson B.I. Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization. Biochemistry 48 (2009) 9227-9436
28. Zibaee S., Jakes R., Fraser G., Serpell L.C., Crowther R.A., and Goedert M. Sequence determinants for amyloid fibrillogenesis of human alpha-synuclein. J. Mol. Biol. 374 (2007) 454-464
29. Biere A.L., Wood S.J., Wypych J., Steavenson S., Jiang Y., Anafi D., Jacobsen F.W., Jarosinski M.A., Wu G.M., Louis J.C., Martin F., Narhi L.O., and Citron M. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than β- and γ-synuclein and cannot cross-seed its homologs. J. Biol. Chem. 275 (2000) 34574-34579
30. Du H.N., Tang L., Luo X.Y., Li H.T., Hu J., Zhou J.W., and Hu H.Y. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. Biochemistry 42 (2003) 8870-8878
31. Rivers R.C., Kumita J.R., Tartaglia G.G., Dedmon M.M., Pawar A., Vendruscolo M., Dobson C.M., and Christodoulou J. Molecular determinants of the aggregation behavior of alpha- and beta-synuclein. Protein Sci. 17 (2008) 887-898
32. Conway K.A., Harper J.D., and Lansbury P.T. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39 (2000) 2552-2563
33. Crystal A.S., Giasson B.I., Crowe A., Kung M.P., Zhuang Z.P., Trojanowski J.Q., and Lee V.M. A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem. 86 (2003) 1359-1368
34. Norris E.H., Giasson B.I., Hodara R., Xu S., Trojanowski J.Q., Ischiropoulos H., and Lee V.M. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280 (2005) 21212-21219
35. Conway K.A., Rochet J.C., Bieganski R.M., and Lansbury Jr. P.T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (2001) 1346-1349
36. Herrera F.E., Chesi A., Paleologou K.E., Schmid A., Munoz A., Vendruscolo M., Gustincich S., Lashuel H.A., and Carloni P. Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS One 3 (2008) e3394
37. Zhu M., Rajamani S., Kaylor J., Han S., Zhou F., and Fink A.L. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279 (2004) 26846-26857
38. Masuda M., Suzuki N., Taniguchi S., Oikawa T., Nonaka T., Iwatsubo T., Hisanaga S.i., Goedert M., and Hasegawa M. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45 (2006) 6085-6094
39. Hong D.P., Fink A.L., and Uversky V.N. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol. 383 (2008) 214-223
40. Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A., and Wanker E.E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15 (2008) 558-566
41. Miake H., Mizusawa H., Iwatsubo T., and Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J. Biol. Chem. 277 (2002) 19213-19219
42. Koo H.J., Lee H.J., and Im H. Sequence determinants regulating fibrillation of human alpha-synuclein. Biochem. Biophys. Res. Commun. 368 (2008) 772-778
43. Glenner G.G. Amyloid deposits and amyloidosis. N. Engl. J. Med. 302 (1980) 1283-1292
44. Naiki H., Higuchi K., Hosokawa M., and Takeda T. Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal. Biochem. 177 (1989) 244-249
45. Levine III H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 2 (1993) 404-410
46. Levine III H., and Scholten J.D. Screening for pharmacologic inhibitors of amyloid fibril formation. Methods Enzymol. 309 (1999) 467-476
47. Klunk W.E., Pettegrew J.W., and Abraham D.J. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 37 (1989) 1273-1281
48. Zhuang Z.P., Kung M.P., Hou C., Skovronsky D.M., Gur T.L., Plossl K., Trojanowski J.Q., Lee V.M.Y., and Kung H.F. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J. Med. Chem. 44 (2001) 1905-1914
49. Eanes E.D., and Glenner G.G. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16 (1968) 673-677
50. Carter D.B., and Chou K.C. A model for structure-dependent binding of Congo red to Alzheimer beta-amyloid fibrils. Neurobiol. Aging 19 (1998) 37-40
51. Klunk W.E., Debnath M.L., and Pettegrew J.W. Chrysamine-G binding to Alzheimer and control brain: autopsy study of a new amyloid probe. Neurobiol. Aging 16 (1995) 541-548
52. Meng X., Munishkina L.A., Fink A.L., and Uversky V.N. Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation. Biochemistry 48 (2009) 8206-8224
53. Chou P.Y., and Fasman G.D. Prediction of protein conformation. Biochemistry 13 (1974) 222-245
54. Chou P.Y., and Fasman G.D. Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins. Biochemistry 13 (1974) 211-222
55. Pawar A.P., Dubay K.F., Zurdo J., Chiti F., Vendruscolo M., and Dobson C.M. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 350 (2005) 379-392
56. Chiti F., Stefani M., Taddei N., Ramponi G., and Dobson C.M. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424 (2003) 805-808
57. Uversky V.N., and Fink A.L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 1698 (2004) 131-153
58. Bemporad F., Calloni G., Campioni S., Plakoutsi G., Taddei N., and Chiti F. Sequence and structural determinants of amyloid fibril formation. Acc. Chem. Res. 39 (2006) 620-627